It comes down to transparency, because while their PTAC had the priorities—high, medium, low, or funded but cost-neutral—we're not sure of the criteria that they've come up with for this. We assume it's what they refer to as the factors for consideration, but it's a question that remains unanswered.
They're not the longest waiting times. We have some recommended medicines that have been on the list for up to two years now. Some of the high-priority ones have been as long as six years. It's a question we can ask, but getting an answer would have to come from Pharmac, unfortunately, not us.